Skip to main content
G

Gan & Lee Pharmaceuticals. — Investor Relations & Filings

Ticker · 603087 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 869 across all filing types
Latest filing 2026-04-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603087

About Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals is a biopharmaceutical company specializing in the research, development, production, and commercialization of insulin analogs and medical devices. The company focuses on diabetes care, offering a comprehensive portfolio that includes insulin glargine, insulin lispro, and insulin aspart, alongside delivery systems such as reusable and disposable insulin pens. Beyond its core expertise in metabolic disorders, the firm is expanding its research pipeline into oncology, cardiovascular diseases, and autoimmune conditions. Utilizing advanced recombinant DNA technology, the company maintains vertically integrated manufacturing capabilities to ensure high-quality therapeutic solutions. Its products are distributed across global markets, aiming to improve the quality of life for patients requiring long-term endocrine management.

Recent filings

Filing Released Lang Actions
战略委员会工作细则（2026年4月）
Governance Information Classification · 1% confidence The document is the internal ‘Work Rules’ for the Board’s Strategic Committee of 甘李药业股份有限公司, detailing the committee’s composition, responsibilities, meeting procedures, decision-making processes, and governance structure. This is an internal governance charter rather than a financial report or announcement. It therefore falls under Governance Information (CGR).
2026-04-22 Chinese
2025年度董事会工作报告
Management Reports Classification · 1% confidence The document is the 2025 Annual Work Report of the Board of Directors of 甘李药业股份有限公司, summarizing the company’s operational performance, R&D, strategy, governance and board activities. It is not a full statutory annual report, not an earnings release or proxy statement, nor an announcement of board changes. It provides detailed management discussion and analysis of financial results and outlook. Therefore it best fits the “Management Reports (MDA)” category.
2026-04-22 Chinese
股东会听取：2025年度独立董事述职报告-昌增益
Governance Information Classification · 1% confidence The document is a 2025 annual performance report (‘述职报告’) by an independent director of 甘李药业, summarizing governance activities, board and committee attendances, internal controls, and compliance with laws/regulations. It is not a financial report (10-K, IR, ER), not an announcement of a vote or dividend, nor an earnings call or capital update. It focuses on board governance practices and the independent director’s duties, which falls under Governance Information (CGR).
2026-04-22 Chinese
公司章程（2026年4月修订）
Governance Information Classification · 1% confidence The document is the full text of 甘李药业股份有限公司’s 公司章程 (Articles of Association), detailing the internal rules, board structure, shareholder rights, meeting procedures, and governance practices. This is precisely a Governance Information document, not an announcement or financial report. Therefore it falls under code CGR.
2026-04-22 Chinese
关于召开2025年年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 1% confidence The document is an announcement (“公告”) by 甘李药业股份有限公司 detailing the time, location, participants, and methods for the 2025 Annual and 2026 Q1 Performance Explanation Meeting (业绩说明会), which is an investor-focused presentation of financial results, strategy, and Q&A. It does not contain the full annual or quarterly report texts, nor is it a transcript or summary of results itself. This clearly aligns with an Investor Presentation (Code: IP).
2026-04-22 Chinese
中伦律师事务所关于甘李药业2022年限制性股票激励计划第三个解除限售期解除限售条件成就、2024年限制性股票激励计划第二个解除限售期解除限售条件成就、回购注销部分限制性股票及调整回购价格的法律意见书
Regulatory Filings Classification · 1% confidence The provided document is a detailed legal opinion (“法律意见书”) issued by Zhong Lun Law Firm on share incentive plans, covering unlocking conditions, repurchase and cancellation of restricted stock, and price adjustments. It is not an earnings release, annual/quarterly report, board change notice, dividend notice, or proxy material. It also is not a pure management discussion (MDA) or investor presentation. Rather, it deals with legal compliance and approvals for equity incentive actions, making it a specialized legal advisory rather than litigation per se. As there is no dedicated category for a legal opinion on equity incentive compliance, it falls into the general fallback category of miscellaneous regulatory or legal filings. Thus, the best classification is Regulatory Filings (RNS).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.